Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""JC Virus"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 188
Tytuł:
Negative association between multiple sclerosis immunogenetic profile and in silico immunogenicities of 12 viruses.
Autorzy:
James LM; The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, 55417, USA.; Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, 55455, USA.; Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, 55455, USA.
Georgopoulos AP; The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, 55417, USA. .; Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, 55455, USA. .; Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, 55455, USA. .; Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, 55455, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 31; Vol. 13 (1), pp. 18654. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Sclerosis*
Herpesvirus 6, Human*/genetics
JC Virus*
Humans ; Immunogenetics ; Europe
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Autorzy:
Ngouth N; Viral Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Monaco MC; Viral Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Walker L; Department of Laboratory Medicine, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Corey S; Neuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Ikpeama I; Department of Laboratory Medicine, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Fahle G; Department of Laboratory Medicine, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Cortese I; Neuroimmunology Clinic, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Das S; Department of Laboratory Medicine, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Jacobson S; Viral Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Jun 08; Vol. 14 (6). Date of Electronic Publication: 2022 Jun 08.
Typ publikacji:
Journal Article
MeSH Terms:
JC Virus*/genetics
Leukoencephalopathy, Progressive Multifocal*/diagnosis
Leukoencephalopathy, Progressive Multifocal*/drug therapy
Multiple Sclerosis*/drug therapy
DNA, Viral/genetics ; Humans ; Natalizumab/therapeutic use ; Real-Time Polymerase Chain Reaction ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
Autorzy:
Prezioso C; IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, 00163 Rome, Italy.; Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, 00185 Rome, Italy.
Grimaldi A; Multiple Sclerosis Clinical and Research Unit, Fondazione Policlinico di Tor Vergata, 00133 Rome, Italy.
Landi D; Multiple Sclerosis Clinical and Research Unit, Fondazione Policlinico di Tor Vergata, 00133 Rome, Italy.; Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
Nicoletti CG; Multiple Sclerosis Clinical and Research Unit, Fondazione Policlinico di Tor Vergata, 00133 Rome, Italy.; Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
Brazzini G; Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, 00185 Rome, Italy.
Piacentini F; Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, 00185 Rome, Italy.
Passerini S; Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, 00185 Rome, Italy.
Limongi D; IRCCS San Raffaele Roma, Telematic University, 00163 Rome, Italy.
Ciotti M; Laboratory of Virology, Polyclinic Tor Vergata Foundation, 00133 Rome, Italy.
Palamara AT; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.; Laboratory Affiliated to Institute Pasteur Italia-Cenci Bolognetti Foundation, Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, 00185 Rome, Italy.
Marfia GA; Multiple Sclerosis Clinical and Research Unit, Fondazione Policlinico di Tor Vergata, 00133 Rome, Italy.; Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.; Unit of Neurology, IRCCS Istituto Neurologico Mediterraneo NEUROMED, 86077 Pozzilli, Italy.
Pietropaolo V; Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, 00185 Rome, Italy.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Aug 25; Vol. 13 (9). Date of Electronic Publication: 2021 Aug 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized/*therapeutic use
Immunologic Factors/*therapeutic use
JC Virus/*drug effects
Leukoencephalopathy, Progressive Multifocal/*etiology
Multiple Sclerosis/*drug therapy
Viral Load/*drug effects
Adult ; Capsid Proteins/genetics ; DNA, Viral/genetics ; Female ; Humans ; JC Virus/classification ; JC Virus/genetics ; JC Virus/pathogenicity ; Leukoencephalopathy, Progressive Multifocal/blood ; Leukoencephalopathy, Progressive Multifocal/urine ; Male ; Middle Aged ; Multiple Sclerosis/blood ; Multiple Sclerosis/complications ; Multiple Sclerosis/urine ; Phylogeny ; Risk Assessment ; Viremia/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab.
Autorzy:
Kolcava J; Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Department of Neurology, University Hospital Brno, Jihlavská 340/20, 625 00, Brno, Czech Republic.
Hulova M; Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Department of Neurology, University Hospital Brno, Jihlavská 340/20, 625 00, Brno, Czech Republic.
Rihova L; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
Bednarik J; Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Department of Neurology, University Hospital Brno, Jihlavská 340/20, 625 00, Brno, Czech Republic.
Stourac P; Faculty of Medicine, Masaryk University, Brno, Czech Republic. .; Department of Neurology, University Hospital Brno, Jihlavská 340/20, 625 00, Brno, Czech Republic. .
Pokaż więcej
Źródło:
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2021 Jul; Vol. 42 (7), pp. 2847-2853. Date of Electronic Publication: 2020 Nov 17.
Typ publikacji:
Journal Article
MeSH Terms:
JC Virus*
Leukoencephalopathy, Progressive Multifocal*
Lymphocytosis*/chemically induced
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
CD8-Positive T-Lymphocytes ; Female ; Humans ; Immunologic Factors/adverse effects ; Natalizumab/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
Autorzy:
Agostini S; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
Mancuso R; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
Costa AS; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
Caputo D; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
Clerici M; IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Mar 12; Vol. 13 (3). Date of Electronic Publication: 2021 Mar 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
JC Virus/*growth & development
MicroRNAs/*urine
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Virus Activation/*drug effects
Antibodies, Viral/blood ; Antigens, Viral, Tumor/biosynthesis ; Biomarkers/urine ; Down-Regulation/genetics ; Female ; Humans ; Immunologic Factors/therapeutic use ; JC Virus/drug effects ; JC Virus/immunology ; Leukoencephalopathy, Progressive Multifocal/virology ; Male ; MicroRNAs/genetics ; Virus Latency/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod.
Autorzy:
Watanabe M; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Nakamura Y; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.; Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, 2-6-11 Yakuin, Chuo-ku, Fukuoka, 810-0022, Japan.; School of Pharmacy at Fukuoka, International University of Health and Welfare, 137-1 Enokizu, Okawa, 831-8501, Japan.
Isobe N; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.; Department of Neurological Therapeutics, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Tanaka M; Kyoto MS Center, Kyoto Min-Iren-Chuo Hospital, 2-1 Uzumasatsuchimoto-cho, Ukyo-ku, Kyoto, 616-8147, Japan.; Department of Neurology, Kaikoukai Jyousai Hospital, 1-4 Kitabatake, Nakamura-ku, Nagoya, 453-0815, Japan.
Sakoda A; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.; Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, 2-6-11 Yakuin, Chuo-ku, Fukuoka, 810-0022, Japan.
Hayashi F; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Kawano Y; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.; Department of Neurology, National Hospital Organization Omuta National Hospital, 1044-1 Oaza, Tachibana, Omuta, 837-0911, Japan.
Yamasaki R; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Matsushita T; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Kira JI; Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. .; Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, 2-6-11 Yakuin, Chuo-ku, Fukuoka, 810-0022, Japan. .; Translational Neuroscience Center, Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare, 137-1 Enokizu, Okawa, 831-8501, Japan. .
Pokaż więcej
Źródło:
Journal of neuroinflammation [J Neuroinflammation] 2020 Jul 09; Vol. 17 (1), pp. 206. Date of Electronic Publication: 2020 Jul 09.
Typ publikacji:
Journal Article
MeSH Terms:
Alleles*
Fingolimod Hydrochloride/*therapeutic use
HLA-DRB1 Chains/*blood
Immunosuppressive Agents/*therapeutic use
JC Virus/*metabolism
Multiple Sclerosis/*blood
Adult ; Aged ; Biomarkers/blood ; Female ; Fingolimod Hydrochloride/pharmacology ; Genetic Predisposition to Disease/genetics ; HLA-DRB1 Chains/genetics ; Humans ; Immunosuppressive Agents/pharmacology ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica.
Autorzy:
Paz SPC; Reference Center for Multiple Sclerosis, Santos, Brazil.
Branco L; Reference Center for Multiple Sclerosis, Santos, Brazil.
Pereira MAC; Neurology, Neuroscience and Headache Institute, Santos, Brazil.
Spessotto C; Neurology, Neuroscience and Headache Institute, Santos, Brazil.
Fragoso YD; Reference Center for Multiple Sclerosis, Santos, Brazil.; Department of Neurology, Universidade Metropolitana de Santos, Santos, Brazil.
Pokaż więcej
Źródło:
Epidemiology and health [Epidemiol Health] 2018 Jan 05; Vol. 40, pp. e2018001. Date of Electronic Publication: 2018 Jan 05 (Print Publication: 2018).
Typ publikacji:
Journal Article; Review; Systematic Review
MeSH Terms:
Global Health/*statistics & numerical data
JC Virus/*isolation & purification
Multiple Sclerosis/*virology
Neuromyelitis Optica/*virology
Antibodies, Viral/blood ; Humans ; JC Virus/immunology ; Multiple Sclerosis/epidemiology ; Neuromyelitis Optica/epidemiology ; Prevalence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Autorzy:
Bertoli D; Centro di Ricerca Emato-oncologica AIL (CREA), Diagnostic Department, ASST Spedali Civili, Brescia, Italy.; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Sottini A; Centro di Ricerca Emato-oncologica AIL (CREA), Diagnostic Department, ASST Spedali Civili, Brescia, Italy.
Capra R; Multiple Sclerosis Center, ASST Spedali Civili, Brescia, Italy.
Scarpazza C; Multiple Sclerosis Center, ASST Spedali Civili, Brescia, Italy.; Department of General Psychology, University of Padova, Padova, Italy.
Bresciani R; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Notarangelo LD; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Imberti L; Centro di Ricerca Emato-oncologica AIL (CREA), Diagnostic Department, ASST Spedali Civili, Brescia, Italy. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Nov 12; Vol. 9 (1), pp. 16605. Date of Electronic Publication: 2019 Nov 12.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
B-Lymphocytes/*immunology
Clone Cells/*immunology
JC Virus/*immunology
Leukoencephalopathy, Progressive Multifocal/*immunology
Multiple Sclerosis/*immunology
T-Lymphocytes/*immunology
T-Lymphocytes, Cytotoxic/*immunology
Genes, T-Cell Receptor beta/genetics ; Humans ; Immunoglobulin Variable Region/genetics ; Immunologic Factors/pharmacology ; Leukoencephalopathy, Progressive Multifocal/drug therapy ; Leukoencephalopathy, Progressive Multifocal/pathology ; Leukoencephalopathy, Progressive Multifocal/virology ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/pathology ; Multiple Sclerosis/virology ; Natalizumab/pharmacology ; Polyomavirus Infections/immunology ; Polyomavirus Infections/virology ; Tumor Virus Infections/immunology ; Tumor Virus Infections/virology ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Autorzy:
Auer M; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Hegen H; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Sellner J; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
Oppermann K; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
Bsteh G; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Di Pauli F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Berger T; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Deisenhammer F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Pokaż więcej
Źródło:
Brain and behavior [Brain Behav] 2019 Jul; Vol. 9 (7), pp. e01332. Date of Electronic Publication: 2019 Jun 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral/*immunology
Immunologic Factors/*therapeutic use
JC Virus/*immunology
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Adult ; Antibodies, Viral/blood ; Cohort Studies ; Denmark ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Humans ; Immunologic Factors/blood ; Longitudinal Studies ; Male ; Multiple Sclerosis/blood ; Multiple Sclerosis/immunology ; Natalizumab/blood ; Prospective Studies ; Seroconversion
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
Autorzy:
Prosperini L; Dept. of Neurology and Psychiatry, Sapienza University, Viale Dell'Università, Rome, Italy.
de Rossi N; Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti, Montichiari, Brescia, Italy.
Scarpazza C; Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti, Montichiari, Brescia, Italy.
Moiola L; Dept. of Neurology, San Raffaele Scientific Institute, Via Olgettina, Milan, Italy.
Cosottini M; Dept. of Translational Research and New Surgical and Medical Technologies, University of Pisa, Via Paradisa, Pisa, Italy.
Gerevini S; Dept. of Neuroradiology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina, Milan, Italy.
Capra R; Multiple Sclerosis Centre, Spedali Civili di Brescia, Via Ciotti, Montichiari, Brescia, Italy.
Pokaż więcej
Corporate Authors:
Italian PML study group
Źródło:
PloS one [PLoS One] 2016 Dec 20; Vol. 11 (12), pp. e0168376. Date of Electronic Publication: 2016 Dec 20 (Print Publication: 2016).
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
JC Virus*
Leukoencephalopathy, Progressive Multifocal*/chemically induced
Leukoencephalopathy, Progressive Multifocal*/diagnostic imaging
Leukoencephalopathy, Progressive Multifocal*/mortality
Leukoencephalopathy, Progressive Multifocal*/physiopathology
Magnetic Resonance Imaging*
Natalizumab*/administration & dosage
Natalizumab*/adverse effects
Multiple Sclerosis/*drug therapy
Multiple Sclerosis/*mortality
Adult ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Multiple Sclerosis/diagnostic imaging ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Treatment of natalizumab-associated PML with filgrastim.
Autorzy:
Stefoski D; Department of Neurological Sciences Rush University Medical Center Chicago Illinois.
Balabanov R; Department of Neurology Northwestern University Chicago Illinois.
Waheed R; Department of Neurological Sciences Rush University Medical Center Chicago Illinois.
Ko M; Department of Neurological Sciences Rush University Medical Center Chicago Illinois.
Koralnik IJ; Department of Neurological Sciences Rush University Medical Center Chicago Illinois.
Sierra Morales F; Department of Neurological Sciences Rush University Medical Center Chicago Illinois.
Pokaż więcej
Źródło:
Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2019 Apr 08; Vol. 6 (5), pp. 923-931. Date of Electronic Publication: 2019 Apr 08 (Print Publication: 2019).
Typ publikacji:
Journal Article
MeSH Terms:
Filgrastim/*therapeutic use
Immunologic Factors/*adverse effects
JC Virus/*drug effects
Leukoencephalopathy, Progressive Multifocal/*drug therapy
Leukoencephalopathy, Progressive Multifocal/*etiology
Multiple Sclerosis/*drug therapy
Natalizumab/*adverse effects
Adult ; Brain/diagnostic imaging ; Disease Progression ; Female ; Humans ; Leukoencephalopathy, Progressive Multifocal/diagnostic imaging ; Magnetic Resonance Imaging ; Male ; Natalizumab/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients.
Autorzy:
Iannetta M; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
Zingaropoli MA; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy. .
Latronico T; Department of Biosciences, Biotechnology and Biopharmaceutics, Aldo Moro University, Bari, Italy.
Pati I; Department of Biosciences, Biotechnology and Biopharmaceutics, Aldo Moro University, Bari, Italy.
Pontecorvo S; Department of Human Neuroscience, Multiple Sclerosis Center, Sapienza University, Rome, Italy.
Prezioso C; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
Pietropaolo V; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
Cortese A; Department of Human Neuroscience, Multiple Sclerosis Center, Sapienza University, Rome, Italy.
Frontoni M; Department of Human Neuroscience, Multiple Sclerosis Center, Sapienza University, Rome, Italy.
D'Agostino C; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
Francia A; Department of Human Neuroscience, Multiple Sclerosis Center, Sapienza University, Rome, Italy.
Vullo V; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
Mastroianni CM; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
Liuzzi GM; Department of Biosciences, Biotechnology and Biopharmaceutics, Aldo Moro University, Bari, Italy.
Ciardi MR; Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Jan 22; Vol. 9 (1), pp. 311. Date of Electronic Publication: 2019 Jan 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
JC Virus/*physiology
Matrix Metalloproteinase 9/*blood
Multiple Sclerosis/*virology
Natalizumab/*therapeutic use
DNA, Viral ; Female ; Humans ; Immunity ; Leukoencephalopathy, Progressive Multifocal/diagnosis ; Leukoencephalopathy, Progressive Multifocal/etiology ; Male ; Multiple Sclerosis/blood ; Multiple Sclerosis/immunology ; Multiple Sclerosis, Relapsing-Remitting ; T-Lymphocytes/immunology ; Virus Activation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Autorzy:
Reuwer AQ; Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital Tilburg, Tilburg, The Netherlands.
Heron M; Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital Tilburg, Tilburg, The Netherlands.
van der Dussen D; Department of Neurology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Schneider-Hohendorf T; Department of Neurology, University of Munster, Munster, Germany.
Murk JL; Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital Tilburg, Tilburg, The Netherlands.
Pokaż więcej
Źródło:
Acta neurologica Scandinavica [Acta Neurol Scand] 2017 Nov; Vol. 136 Suppl 201, pp. 37-44.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Polyomavirus Infections*/immunology
Polyomavirus Infections*/virology
Tumor Virus Infections*/immunology
Tumor Virus Infections*/virology
Antibodies, Viral/*blood
Immunologic Factors/*adverse effects
JC Virus/*immunology
Leukoencephalopathy, Progressive Multifocal/*immunology
Multiple Sclerosis/*drug therapy
Natalizumab/*adverse effects
Adaptive Immunity/physiology ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Humans ; Immunologic Factors/therapeutic use ; Immunosuppressive Agents/adverse effects ; Leukoencephalopathy, Progressive Multifocal/virology ; Multiple Sclerosis/complications ; Natalizumab/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Autorzy:
Dominguez-Mozo MI; Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Rus M; Hospital Universitario Virgen Macarena, Sevilla, Spain.
Santiago JL; Immunology Department, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Izquierdo G; Hospital Universitario Virgen Macarena, Sevilla, Spain.
Casanova I; Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Galan V; Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Garcia-Martinez MA; Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Arias-Leal AM; Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
García-Montojo M; Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Pérez-Pérez S; Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Arroyo R; Hospital Universitario Quirón Salud Madrid, Madrid, Spain.
Alvarez-Lafuente R; Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Pokaż więcej
Źródło:
European journal of clinical investigation [Eur J Clin Invest] 2017 Feb; Vol. 47 (2), pp. 158-166.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antibodies, Viral/*metabolism
Immunologic Factors/*therapeutic use
JC Virus/*immunology
Leukoencephalopathy, Progressive Multifocal/*immunology
Multiple Sclerosis/*immunology
Natalizumab/*therapeutic use
Adult ; Aged ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Spain
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anti-JC virus seroprevalence in a Finnish MS cohort.
Autorzy:
Kolasa M; Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland.
Hagman S; Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland.
Verkkoniemi-Ahola A; Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland.
Airas L; Department of Clinical Neurosciences, Turku University Hospital, Turku, Finland.
Koivisto K; Department of Neurology, Seinäjoki Central Hospital, Seinäjoki, Finland.
Elovaara I; Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland.
Pokaż więcej
Źródło:
Acta neurologica Scandinavica [Acta Neurol Scand] 2016 May; Vol. 133 (5), pp. 391-7. Date of Electronic Publication: 2015 Sep 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukoencephalopathy, Progressive Multifocal/*blood
Multiple Sclerosis/*epidemiology
Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Viral/blood ; Female ; Finland ; Humans ; JC Virus/immunology ; Leukoencephalopathy, Progressive Multifocal/epidemiology ; Male ; Middle Aged ; Multiple Sclerosis/complications ; Multiple Sclerosis/drug therapy ; Natalizumab/therapeutic use ; Prevalence ; Serologic Tests
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Natalizumab in Multiple Sclerosis: Long-Term Management.
Autorzy:
Clerico M; Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. .
Artusi CA; Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. .
Liberto AD; Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. .
Rolla S; Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. .
Bardina V; Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. .
Barbero P; Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. .
Mercanti SF; Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. .
Durelli L; Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy. .
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2017 Apr 29; Vol. 18 (5). Date of Electronic Publication: 2017 Apr 29.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antibodies, Monoclonal/*therapeutic use
Immunologic Factors/*therapeutic use
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Adrenal Cortex Hormones/therapeutic use ; Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; JC Virus/isolation & purification ; Leukoencephalopathy, Progressive Multifocal/diagnosis ; Leukoencephalopathy, Progressive Multifocal/etiology ; Natalizumab/administration & dosage ; Natalizumab/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
Autorzy:
Hegen H; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Auer M; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Bsteh G; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Di Pauli F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Plavina T; Biogen, Cambridge, Massachusetts, United States of America.
Walde J; Department of Statistics, Faculty of Economics and Statistics, University of Innsbruck, Innsbruck, Austria.
Deisenhammer F; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Berger T; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2017 Mar 20; Vol. 12 (3), pp. e0174005. Date of Electronic Publication: 2017 Mar 20 (Print Publication: 2017).
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral/*blood
JC Virus/*immunology
Multiple Sclerosis/*blood
Multiple Sclerosis/*immunology
Adolescent ; Adult ; Aged ; Antibodies, Viral/drug effects ; Disease Progression ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Humans ; Immunologic Factors/therapeutic use ; Longitudinal Studies ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/virology ; Natalizumab/therapeutic use ; Prognosis ; ROC Curve ; Retrospective Studies ; Seroconversion/drug effects ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.
Autorzy:
Evangelopoulos ME; a 1 Demyelinating Diseases Unit, Department of Neurology, Eginition Hospital , University of Athens , Athens , Greece.
Koutoulidis V; b 2 Department of Radiology, Aretaieion Hospital , University of Athens , Athens , Greece.
Andreadou E; a 1 Demyelinating Diseases Unit, Department of Neurology, Eginition Hospital , University of Athens , Athens , Greece.
Evangelopoulos DS; c 3 3rd Department of Orthopaedic Surgery, KAT Hospital , University of Athens , Athens , Greece.
Kilidireas C; a 1 Demyelinating Diseases Unit, Department of Neurology, Eginition Hospital , University of Athens , Athens , Greece.
Pokaż więcej
Źródło:
The International journal of neuroscience [Int J Neurosci] 2016 Dec; Vol. 126 (12), pp. 1097-102. Date of Electronic Publication: 2016 Jan 04.
Typ publikacji:
Journal Article
MeSH Terms:
Adrenal Cortex Hormones/*therapeutic use
Fingolimod Hydrochloride/*therapeutic use
Immunologic Factors/*administration & dosage
Leukoencephalopathy, Progressive Multifocal/*prevention & control
Methylprednisolone/*therapeutic use
Multiple Sclerosis/*drug therapy
Natalizumab/*administration & dosage
Adult ; Cohort Studies ; Disability Evaluation ; Female ; Humans ; JC Virus/immunology ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Multiple Sclerosis/diagnostic imaging ; Multiple Sclerosis/virology ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
Autorzy:
Diotti RA; Laboratorio di Microbiologia e Virologia, Università 'Vita-Salute' San Raffaele, Milan 20132, Italy. .
Capra R; Multiple Sclerosis Center, Spedali Civili of Brescia, Brescia 25123, Italy. .
Moiola L; Neurological Department, IRCCS Hospital San Raffaele, Milan 20132, Italy. .
Caputo V; Laboratorio di Microbiologia e Virologia, Università 'Vita-Salute' San Raffaele, Milan 20132, Italy. .
De Rossi N; Multiple Sclerosis Center, Spedali Civili of Brescia, Brescia 25123, Italy. .
Sangalli F; Neurological Department, IRCCS Hospital San Raffaele, Milan 20132, Italy. .
Martinelli V; Neurological Department, IRCCS Hospital San Raffaele, Milan 20132, Italy. .
Burioni R; Laboratorio di Microbiologia e Virologia, Università 'Vita-Salute' San Raffaele, Milan 20132, Italy. .; Ospedale San Raffaele, Milan 20132, Italy. .
Clementi M; Laboratorio di Microbiologia e Virologia, Università 'Vita-Salute' San Raffaele, Milan 20132, Italy. .; Ospedale San Raffaele, Milan 20132, Italy. .
Mancini N; Laboratorio di Microbiologia e Virologia, Università 'Vita-Salute' San Raffaele, Milan 20132, Italy. .; Ospedale San Raffaele, Milan 20132, Italy. .
Pokaż więcej
Źródło:
Viruses [Viruses] 2016 May 07; Vol. 8 (5). Date of Electronic Publication: 2016 May 07.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
Immunologic Factors/*therapeutic use
JC Virus/*immunology
Multiple Sclerosis/*drug therapy
Multiple Sclerosis/*immunology
Natalizumab/*therapeutic use
Adult ; Capsid Proteins/immunology ; Female ; Humans ; Male ; Middle Aged ; Pilot Projects ; Prospective Studies ; Serum/chemistry ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 188

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies